key: cord-0862188-2z6boube
authors: de Miranda Soriano, Rafaela Vale; Rossi Neto, Joao Manoel; Finger, Marco Aurelio; dos Santos, Carolina Casadei; Lin‐Wang, Hui Tzu
title: COVID‐19 in heart transplant patients: Case reports from Brazil
date: 2021-05-24
journal: Clin Transplant
DOI: 10.1111/ctr.14330
sha: 46fd04ee846a4065b860537eb470820b1ca98de8
doc_id: 862188
cord_uid: 2z6boube

INTRODUCTION: The COVID‐19 pandemic continues, with a late hyperinflammatory phase. The immunosuppressive therapy used in heart transplant patients, in theory, could reduce inflammation thus benefitting patients with COVID‐19. So far, however, there is still very little literature on this subject. METHODS: This is a single‐center retrospective study. We described laboratory parameters and clinical outcomes from 11 heart transplant patients with COVID‐19 assisted at Dante Pazzanese Institute of Cardiology between March and July 2020. RESULTS: Patients with ages between 35 to 79 years, and heart transplantation occurred from 3 to 264 months. The main comorbidities were diabetes mellitus (9/11; 81.8%), hypertension (10/11; 90.9%), and chronic renal disease (6/11; 54.5%). Cyclosporine A was used in 10 (90.9%) patients, mycophenolate mofetil in 9 (81.8%), and mTOR inhibitor in 5 (45.5%). Fever and cough were observed in 8 (72.7%) patients, and dyspnea and gastrointestinal symptoms in 5 (45.5%). Lymphopenia was observed in 10 (90.9%) and thrombocytopenia in 5 (45.5%). The higher level of troponin associated with chest tomography above 50% infiltrates of ground‐glass opacity (GGO) was observed in those with the worst outcomes. Nine patients needed intensive care, and hospital stay ranged from 4 to 21 days, with 2 (18.2%) patients requiring vasopressor drugs and mechanical ventilation, and three patients (27.3%) dying due to COVID‐19 complications. CONCLUSION: Heart transplant patients had the similar symptoms and outcomes as general population; immunosuppressive therapy seems not to have protected them. Patients who presented higher levels of troponin and D‐dimer, associated to greater GGO pulmonary infiltrates had worse outcomes. More studies with larger cohorts may clarify immunosuppressive effects on COVID‐19 outcomes.

The SARS-CoV-2 coronavirus is responsible for the coronavirus disease 2019 ; the SARS-CoV-2 infection continues to spread globally with devastating results, and it is considered by the World Health Organization (WHO) as a pandemic disease 1 .

COVID-19 has also been responsible for many deaths around the world, including Brazil.

According to the Brazilian Health Ministry, 358,425 individuals died up to April 14 st , 2021, and the lethality was 2.6% 2 .

In theory, one might anticipate a higher attack rate of pneumonia, acute respiratory syndrome, and septic shock for organ transplant recipients 3 . However, immunosuppression can inhibit the secondary hyperinflammation caused by a cytokine storm, responsible by the majority of deaths from COVID-19 4 . Similarly, it can lead to atypical clinical presentations or increasing the risk to adverse events 5 . Herein, we report a single-center retrospective study from heart transplant patients with COVID-19, as a preliminary observational context to inform treatment and clinical outcomes.

This study was approved by Dante Pazzanese Institute of Cardiology institutional review board (protocol 4.433.303), which was conducted in accordance to the resolution 466 by the Brazilian Health Council/National Health Surveillance Agency and ICH-GCP for good clinical practices.

This article is protected by copyright. All rights reserved Of the 145 adult heart transplant recipients routinely followed in our institution between March and July 2020, 11 of them presented to our institution for Covid-19 care and were included in this study. After heart transplantation, all patients received standard immunosuppressive regimen with cyclosporine at a 4 mg/kg/day dose, mycophenolate mofetil at a 1.5 g/day dose, and prednisone at a 0.4 mg/kg daily dose. Alternative immunosuppressive therapy was prescribed whenever necessary. All data, such as clinical history, laboratory results, inflammatory and radiological issues, and specific drugs used were retrospectively collected.

The primary outcome was death caused by COVID-19; a secondary outcome was the need for Intensive Care Unit (ICU), mechanical ventilation, along with acute renal dysfunction.

To extract SARS-CoV-2 nucleic acids from nasopharyngeal swabs, the QIAamp® Viral 

Enzyme linked immunosorbent assay (ELISA) was applied to detecting IgG anti SARS-CoV-2 protein N (GenBank: QIG56001.1) in serum of patients. The 96 well plates were firstly adsorbed with 1ug/ml of N protein, incubated overnight at 4°C, and blocked with 1% bovine serum albumin diluted in PBS buffer for 1h at 37 o C, then incubated with the serum (dilution 1/100) for 2h at 37°C. The HRP Anti-human IgG secondary antibody (Sigma-USA) at 1:30000 of dilution was added and incubated at 37°C for 1 hour. The TMB substrate (Thermo-USA) was added in each well and stopped with 1N HCl after 3 min incubation. The absorbance was read at 450nm. The cut-off value assumed was 0.450 AU.

The age of patients enrolled was between 35 and 79 years. The main comorbidities were diabetes mellitus (9/11; 80%), hypertension (10/11; 90%), and chronic renal disease (6/11; 54%). Heart transplantation ranged from 3 to 264 months. Cyclosporine A was used in 10 patients (90%), mTOR inhibitor in 45% (5/11), and mycophenolate in 80% (9/11) patients. Immunosuppression was discontinued in two patients, one had septic shock, the other had severe leukopenia (270/mm 3 ), and both died. Common symptoms at onset of illness were fever and cough in 72% of cases, dyspnea and gastrointestinal symptoms in 45% (Table 1) .

Regarding laboratory parameters at admission or routine follow-up, lymphopenia (< 1,5/1,000mm 3 ) was observed in 90% (10/11) of cases, and thrombocytopenia (< 150/1,000mm 3 ) in almost 50% (5/11). Troponin was higher in two out of three patients who died. Increased inflammatory markers were common, and higher in those requiring the intensive care (Table 2) .

Chest tomography was performed in 82% (9/11) of patients, six presented less than 50% of bilateral pulmonary infiltrates with ground glass opacity (GGO), and three had more than 50% of GGO image associated to worse prognosis (Table 3) .

Only one patient received hydroxychloroquine as alternative therapy for COVID-19. None of the patients received Remdesivir, because it was not approved for clinical use in our country until the time of this study. Hospital stay was four to 21 days, with death occurring in 3 patients (27.3%). Vasopressors and mechanical ventilation were used in 20% of patients. None patient received extracorporeal membrane oxygenation (Table 3) .

In this study, we described eleven COVID-19 cases from a heart transplant patients cohort routinely followed up in our hospital, including nine cases of severe or critical Covid-19, and 2 cases of mild-to-moderate ambulatory Covid-19. The nine severe or critical Covid-19 patients sought emergency care due to difficult breathing and all of them were hospitalized. The two mild-to-moderate cases were minimally asymptomatic, suspected of Sars-CoV-2 infection during a routine visit, confirmed by serology around two months after Covid-19 symptoms, and therefore they did not go through thoracic tomography as well.

This article is protected by copyright. All rights reserved Notably, at the beginning of pandemic outbreak, all nasopharyngeal swabs were tested at government-designated referral laboratory, and samples were missed by logistic services (2 cases with RT-PCR results lost and other 2 cases no longer in the acute phase of infection during routinely follow-up).

We observed a 27% (3/11) mortality rate, slightly higher than in another study 7 which observed 15% (2/13). However, our result was close to that found by Latif et al. 8 (32%; 7/22) and Bottio et al. 9 (29.7%; 14/47), the largest cases in this population to date, which the authors observed a double fatality rate in heart transplant recipients than in general population. The most common symptoms observed in our study group were similar to the report described in Spain 10 , as well as in a multi-center study from Italy 9 .

Four patients (36%) in this study required intensive care, all with higher than 1000ng/mL D-dimer, three with above 50% bilateral pulmonary infiltrates and worse clinical outcomes, progressing to death. Although our hospital offers venous-arterial extracorporeal membrane oxygenation (VA-ECMO), one elder patient opted for palliative treatment and the family refused this treatment. Two others patients did not fulfill the ELSO guidelines 11 ,and both died of septic shock.

suggesting possible disseminated intravascular coagulation. Furthermore, the group which received low molecular weight heparin had a lower mortality rate 15, 16 . Interestingly, like Singhvi et al 17 , no episodes of thromboembolic event were observed in our study.

Half of our patients had higher than 1000ng/mL D-dimer none of them treated with anticoagulant therapy, because it was not recommended by the institutional guideline at that time. It is worth to mention that D-dimer is not routinely assessed in our service then most of our patients have not baseline values assessed.

In this study, patients who had elevated circulating troponin, often present hemodynamic instability, vasoactive drugs were required and had worst outcomes, as the literature points out 18 . Furthermore, patients suffering from viral sepsis usually present myocardial injury and elevate circulating troponin. The cardiac troponin concentration is associated with early mortality, as well as post discharge cardiovascular morbidity 19 .

The number of patients with lymphopenia (< 1,5/1,000mm 3 ) and thrombocytopenia (< 150/1,000mm 3 ) was higher in this study, 90% (10/11) and 45% (5/11), respectively,

This article is protected by copyright. All rights reserved versus previous reports in non-transplanted and transplanted populations 20, 21 . This was likely due to the use of immunosuppressant or an additional symptom of COVID-19.

Although in vitro studies suggest that mycophenolate mofetil is inhibitor of coronaviruses 22 , and the interferon alpha combined with cyclosporine therapy was effective in reducing MERS-CoV replication 23 . On the other hand, immunosuppressive therapy can increase susceptibility to the infection, decreasing an effective response to the treatment. The high mortality rate in this study does not suggest beneficial protection of immunosuppression; further randomized studies are necessary to assess each immunosuppressant individually.

The small cohort from a sole transplantation center is one major limitation of this study.

However, it seems to be a common limitation in studies involving heart transplant patients infected by SARS-CoV-2. One must acknowledge that we did not routinely test all patients; therefore, we might have underestimated the prevalence of COVID-19 in patients with heart transplant. Unfortunately, given the limited national resources, it was possible only to test symptomatic individuals.

It is not possible to draw conclusions as to specific therapies for COVID-19, or in managing immunosuppression, from a small observational, non-interventional study such as this. However, it does provide insight into the scope and magnitude of the burden of the disease. We hope that data described herein could help to clarify the pathogeneses of COVID-19 into the heart transplant context.

Heart transplant patients had comparable symptoms and outcomes as the general population; the immunosuppressive therapy background did not appear to protect them.

Patients who presented higher levels of troponin and D-dimer with higher GGO pulmonary infiltrates had worse outcomes. Studies with larger cohorts may contribute to clarifying the immunosuppressive effect on COVID-19 outcomes.

The authors have no conflicts of interest regarding the content of this manuscript. 

This article is protected by copyright. All rights reserved Troponin I (ng/L) D-dimer (ng/mL) C-reative protein (mg/dL) B-type Natriuretic peptide (pg/mL) Inpatients/ outpatients*

The epidemiology and clinical information about COVID-19

Influenza and other respiratory virus infections in solid organ transplant recipients

COVID-19: consider cytokine storm syndromes and immunosuppression

First cases of COVID-19 in heart transplantation from

Coronavirus Disease-2019 in Heart Transplant Recipients in Southeastern Michigan: A Case Series

Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease

COVID-19 in heart transplant recipients: a multi-center analysis of the Northern Italian outbreak. JACC Hear Fail

COVID-19 in solid organ transplant Accepted Article This article is protected by copyright. All rights reserved recipients: A single-center case series from Spain

Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19)

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Venous thromboembolism in COVID-19 patients

Challenges in heart transplantation during COVID-19: A singlecenter experience

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Myocardial Injury in Patients With Sepsis and Its Association With Long-Term Outcome

Clinical features of severe patients infected with Accepted Article

Covid-19 and Kidney Transplantation

High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses

Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model

Accepted Article

This article is protected by copyright. All rights reservedWe would like to thank Marcia Ferreira Maluf for writing and editorial support.

This article is protected by copyright. All rights reserved